[Show abstract][Hide abstract] ABSTRACT: Abstract Objective: Patients with both major depression and personality disorders have a high risk of suicidal behaviour. Lithium is meant to have antisuicidal properties in patients with affective disorders. The antisuicidal effect of lithium in patients with affective disorders and comorbid personality disorders has not been investigated yet. Methods: A post-hoc analysis of a subsample of patients with depression and comorbid personality disorder and a recent suicide attempt (n=19) from the prospective, placebo-controlled lithium intervention study (N = 167), was conducted. Results: Three patients in the lithium group (n=8) and two patients in the placebo group (n=11) presented a suicide attempt throughout the course of the study. No differences between the placebo and lithium group related to suicidal behaviour could be detected. Conclusions: On the basis of the small sample size, among patients with comorbid personality disorder, lithium does not seem to have an effect on suicidal behaviour in contrast to patients with affective disorders without comorbid personality disorder.
International Journal of Psychiatry in Clinical Practice 07/2014; · 1.31 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Evidence based on controlled studies is still limited for treatment strategies that prevent recurrence of suicide attempts. Findings from observational as well as meta-analytic studies strongly suggest that lithium may have suicide-protective properties.
Patients with a recent suicide attempt in the context of an affective spectrum disorder (n = 167) were treated with either lithium or placebo during a 12-month period.
Survival analysis showed no significant difference of suicidal acts between lithium and placebo-treated individuals (adjusted hazard ratio 0.517; 95% CI 0.18-1.43). However, post hoc analysis revealed that all completed suicides had occurred in the placebo group accounting for a significant difference in incidence rates (P = 0.049).
Results indicate that lithium treatment might be effective in reducing the risk of completed suicide in adult patients with affective disorders. Our findings contribute to the growing body of evidence suggesting a specific antisuicidal effect of lithium.
[Show abstract][Hide abstract] ABSTRACT: Several studies have shown that there is a significantly increased risk of suicide related mortality in patients with a positive history of suicide attempts. The SUPLI-Study is the first prospective, randomized, double blind, placebo controlled multi-center trial focusing on the proposed suicide preventive effects of lithium in patients with suicidal behavior but not suffering from bipolar disorder or recurrent major depressive disorder. Patients with a recent history of a suicide attempt are treated with lithium versus placebo during a 12 month period. The hypothesis is that lithium treatment will lead to a 50% reduction of suicidal behavior. The protocol of the study and preliminary results are presented.
Archives of Suicide Research 02/2005; 9(1):27-34. · 1.53 Impact Factor